REFRaME-L1: Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 23, 2025 - P2 | N=0 | Withdrawn | Sponsor: Sutro Biopharma, Inc. | N=43 ➔ 0 | Trial completion date: Oct 2026 ➔ May 2025 | Recruiting ➔ Withdrawn | Trial primary completion date: Oct 2026 ➔ May 2025
Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|